Octostim (Desmopressin Acetate)

Desmopressin Acetate acts on the vasopressin pathway to control water reabsorption and haemostatic function.

• Central diabetes insipidus: helps normalize urine output and thirst control.
• Nocturnal enuresis (bedwetting) in children: reduces nighttime urine production.
• Mild haemophilia A and von Willebrand disease: raises plasma levels of factor VIII and von Willebrand factor to improve clotting.

• Desmopressin acetate is a synthetic analogue of the natural hormone vasopressin. It binds selectively to V2 receptors in the renal collecting ducts, stimulating cyclic AMP production and promoting insertion of aquaporin‑2 water channels, which increases water reabsorption. The same V2‑receptor activation on endothelial cells triggers release of stored factor VIII and von Willebrand factor, enhancing haemostasis.

Desmopressin may cause a range of adverse reactions, from mild to potentially serious.

Common Side Effects

• Headache: mild to moderate intensity.
• Nasal irritation or discharge (if administered intranasally).
• Nausea or abdominal discomfort.
• Hyponatraemia: mild reduction in blood sodium levels.
• Flushing or feeling of warmth.

Serious or Rare Side Effects

• Severe hyponatraemia leading to seizures or coma.
• Thromboembolic events such as deep‑vein thrombosis.
• Allergic reactions including rash, itching or anaphylaxis.
• Pulmonary oedema in patients with compromised cardiac function.

Desmopressin requires careful monitoring in several clinical situations.

• Fluid intake: limit excessive fluids to reduce hyponatraemia risk.
• Cardiac or renal disease: assess volume status before use.
• Hyponatraemia history: check baseline sodium levels.
• Concomitant anticoagulants: monitor clotting parameters.
• Pregnancy and lactation: use only if clearly needed.

Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Desmopressin can interact with several medicines that affect fluid balance or coagulation.

Major Interactions (Avoid)

• NSAIDs (e.g., ibuprofen, naproxen): increase risk of hyponatraemia.
• Carbamazepine and other enzyme‑inducing antiepileptics: reduce desmopressin effectiveness.
• Anticoagulants (warfarin, DOACs): may enhance bleeding risk when used for haemostatic indications.

Moderate Interactions (Monitor Closely)

• Diuretics (especially thiazides): potentiate water retention and hyponatraemia.
• Selective serotonin reuptake inhibitors (SSRIs): modestly increase hyponatraemia risk.
• Hormonal contraceptives: may alter fluid balance, requiring sodium monitoring.